Michael Hahalyak, DO
Family Medicine · Irwin, PANPI 1306889605
Payments from drug & device makers
Across 561 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Pfizer$950
- AbbVie$884
- Novo Nordisk$791
- Lilly USA, LLC$563
- AstraZeneca$518
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,150100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 141 | $2,189 |
| Pfizer | 69 | $950 |
| AbbVie(2 entities) | 49 | $884 |
| Novo Nordisk | 45 | $791 |
| Lilly USA, LLC | 34 | $563 |
| AstraZeneca | 28 | $518 |
| Amgen(2 entities) | 30 | $504 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $484 |
| Daiichi Sankyo Inc. | 18 | $327 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $271 |
| Johnson & Johnson | 16 | $250 |
| Merck | 14 | $232 |
| Exact Sciences | 11 | $196 |
| Bayer | 7 | $132 |
| Novartis | 7 | $100 |
| Teva Pharmaceuticals USA, Inc. | 7 | $98 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $80 |
| Grifols USA, LLC | 4 | $71 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Eisai Inc. | 3 | $49 |
| Vertical Pharmaceuticals, LLC | 3 | $47 |
| Abbott | 3 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Biogen | 2 | $28 |
| Upsher-smith Laboratories LLC | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Inari Medical, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $13 |
How this compares
$9,150 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $117,138 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $98,394 |
| JanuviaSitagliptin Phosphate | 33 | $39,321 |
| OzempicSemaglutide | 20 | $34,211 |
| ProliaDenosumab | 16 | $27,257 |
| RybelsusSemaglutide | 17 | $24,287 |
| XareltoRivaroxaban | 21 | $21,650 |
| JardianceEmpagliflozin | 23 | $20,645 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $19,840 |
| TrintellixVortioxetine Hydrobromide | 31 | $15,369 |
| LinzessLinaclotide | 11 | $13,345 |
| TradjentaLinagliptin | 14 | $11,563 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,826 |
| LyricaPregabalin | 12 | $6,734 |
| Spiriva HandihalerTiotropium Bromide | 14 | $6,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $2,189 | $127,694166 claims |
| PfizerEliquis, Lyrica | $950 | $123,872103 claims |
| Novo NordiskOzempic, Rybelsus | $791 | $58,49837 claims |
| MerckJanuvia | $232 | $39,32133 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $16 | $38,20149 claims |
| AmgenProlia | $504 | $27,25716 claims |
| Johnson & JohnsonXarelto | $250 | $21,65021 claims |
| AbbVieLinzess, Synthroid | $884 | $15,63881 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $484 | $15,36931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Irwin
- Mary ZakutneyIrwin$393K
- James LimIrwin$210K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.